Maria Cinta Cid
Autoimmune Diseases Department Medical InternistResearch group
- Systemic vasculitis Group leader (R4)
Featured publications
-
Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis
Authors: Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME .Reference: Journal Of Allergy And Clinical Immunology 2019. -
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial
Authors: Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, de Zoysa J, Espigol-Frigolé G, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Harper L, Jayne D, European Vasculitis Study Group (EUVAS).Reference: Annals Of The Rheumatic Diseases 2019. -
Expression and function of IL12/23 related cytokine subunits (p35, p40, and p19) in giant-cell arteritis lesions: Contribution of p40 to Th1-and Th17-mediated inflammatory pathways
Authors: Espígol-Frigolé G; Planas-Rigol E; Lozano E; Corbera-Bellalta M; Terrades-García N; Prieto-González S; García-Martínez A; Hernández-Rodríguez J; Grau J; Cid M.Reference: Frontiers In Immunology 2018. -
Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: A mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis
Authors: Planas-Rigol E; Terrades-Garcia N; Corbera-Bellalta M; Lozano E; Alba M; Segarra M; Espígol-Frigolé G; Prieto-González S; Hernández-Rodríguez J; Preciado S; Lavilla R; Cid M.Reference: Annals Of The Rheumatic Diseases 2017. -
Trial of Tocilizumab in Giant-Cell Arteritis.
Authors: Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schett G; Schulze-Koops H; Spiera R; Unizony SH; Collinson N .Reference: New England Journal Of Medicine 2017. -
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Authors: Wechsler, M E; Akuthota, P; Jayne, D; Khoury, P; Klion, A; Langford, C A; Merkel, P A; Moosig, F; Specks, U; Cid, M C; Luqmani, R; Brown, J; Mallett, S; Philipson, R; Yancey, S W; Steinfeld, J; Weller, P F; Gleich, G J;EGPA Mepolizumab Study Team.Reference: New England Journal Of Medicine 2017. -
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
Authors: Carmona FD, Vaglio A, Mackie SL, Hernández-Rodríguez J, Monach PA, Castañeda S, Solans R, Morado IC, Narváez J, Ramentol-Sintas M, Pease CT, Dasgupta B, Watts R, Khalidi N, Langford CA, Ytterberg S, Boiardi L, Beretta L, Govoni M, Emmi G, Bonatti F, Cimmino MA, Witte T, Neumann T, Holle J, Schönau V, Sailler L, Papo T, Haroche J, Mahr A, Mouthon L, Molberg Ø, Diamantopoulos AP, Voskuyl A, Brouwer E, Daikeler T, Berger CT, Molloy ES, O'Neill L, Blockmans D, Lie BA, Mclaren P, Vyse TJ, Wijmenga C, Allanore Y, Koeleman BPC,, Barrett JH, Cid MC, Salvarani C, Merkel PA, Morgan AW, González-Gay MA, Martín J Spanish CGA Group, UKGCA Consortium, Vasculitis Clinical Research Consortium.Reference: American Journal Of Human Genetics 2017. -
Blocking interferon gamma reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis
Authors: Corbera-Bellalta M, Planas-Rigol E, Lozano E, Terrades-García N, Alba MA, Prieto-González S, García-Martínez A, Albero R, Enjuanes A, Espígol-Frigolé G, Hernández-Rodríguez J, Roux-Lombard P, Ferlin WG, Dayer JM, Kosco-Vilbois MH, Cid MC .Reference: Annals Of The Rheumatic Diseases 2016. -
Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling
Authors: Espígol-Frigolé G, Planas-Rigol E, Ohnuki H, Salvucci O, Kwak H, Ravichandran S, Luke B, Cid MC, Tosato G .Reference: Science Signaling 2016. -
Changes in biomarkers after therapeutic intervention in temporal arteries cell arteritis
Authors: Corbera-Bellalta, Marc; Garcia-Martinez, Ana; Lozano, Ester; Planas-Rigol, Ester; Tavera-Bahillo, Itziar; Alba, Marco A; Butjosa, Montserrat; Espigol-Frigole, Georgina; Hernandez-Rodriguez, Jose; Fernandez, Pedro L; Roux-Lombard, Pascale; Dayer, Jean-Michel; Rahman, Mahboob U; Cid, Maria C.Reference: Annals Of The Rheumatic Diseases 2014.
Featured Projects
-
Perfil de expresión génica en linfocitos T CD4+ de pacientes con granulomatosis eosinofílica con poliangiítis o Sde. de Churg-Strauss
Principal investigator: Georgina Espigol-Frigole, Georgia Espigol-FrigoleFunder: Instituto de Salud Carlos III (ISCIII)Code: PI18/00461Duration: 01/07/2019 - 31/12/2021 -
Effects of blocking IL-6 receptor with tocilizumab on ex-vivo cultured arteries from patients with giant-cell arteritis. Searching for predictors of response
Principal investigator: Maria Cinta Cid XutglaFunder: International vasculitis FoundationCode: VASCFOUND_RG_18_01Duration: 01/06/2019 - 31/05/2020 -
Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET
Principal investigator: Maria Cinta Cid Xutgla, Patricia Pérez GalánFunder: Ministerio de Economia y Competitividad (MINECO) (Patrocinador)Code: SAF 2017- 88275-RDuration: 01/01/2018 - 31/12/2020 -
Development of ascending aorta dilatation and coronary aneurysms in patients with systemic vasculitis (giant-cell arteritis and Kawasaki disease respectively). Role of HIF signaling in abnormal vascular remodeling and inflammation
Principal investigator: Maria Cinta Cid XutglaFunder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Fundació La Marató de TV3Code: Marató TV3 2014/201507Duration: 01/01/2016 - 01/01/2018 -
Vasculitis de pequeño vaso rodeando una arteria temporal preservada: significado clínico y búsqueda de biomarcadores con utilidad diagnóstica
Principal investigator: Georgina Espigol FrigoleFunder: Instituto de Salud Carlos III (ISCIII)Code: PI15/00092Duration: 01/01/2016 - 31/07/2019